Of course, you should be buy low and sell high. And there are a lot of low prices at the moment. But now might not be the time to buy anything and everything. So what should you buy?
On next Wednesday, 17 October, Canada will officially legalise cannabis. They have had a legal medicinal market for years now. And we’re already seeing some of the world’s biggest cannabis stocks (mostly Canadian) rocket higher in price.
Individual small-caps, because of their tiny size, can move independently of the market. They can be driven by company-specific news, rather than the big global stories.
Nobody wants to get rich slowly. Not millennials, not generation X, not even baby boomers. It’s why there was so much demand for bitcoin last year. It’s also why a good chunk of investors are so interested in cannabis stocks now.
You’ll sometimes hear these big funds referred to as ‘the smart money’. That’s because they’ve got a lot of researchers digging up details on stocks that ‘ordinary’ investors won’t have access to. But here’s the catch.
Don’t be fooled into thinking large-cap stocks are the arena to play in. That’s the mainstream fooling you into a false sense of security.
Despite a small dip in share price in today’s market — investors shouldn’t be too worried. Just think, at the start of this year on Tuesday 2 January, CSL shares were only trading at 140.55. That’s an increase of 40.93% in as little as seven months. Why the increase? Find out here...
Domino’s Pizza Enterprises Ltd [ASX:DMP] shares made a comeback this morning after dropping by almost 9% to $49 a share following downgrades. The share price currently stands at $49.03. Both Citi and Credit Suisse downgraded the popular pizza chain yesterday to a sell value even after recent share price gains. There have also been concerns over franchise operations in recent months.
We all know the biblical story of how David defeated Goliath. But how we can apply that valuable lesson to today's digital landscape?
What is Project: Shivom? It's the next big thing. It will usher in an unprecedented era of medical marvels and create a genomic data market worth billions of dollars.